Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer

In this systematic review and meta-analysis, neoadjuvant anti-PD-1/PD-L1 immunotherapy for resectable HNSCC was well tolerated and may confer therapeutic advantages implied by histopathological response. Long-term outcomes are awaited.